FDA Releases Guidance on Including Cardiovascular Outcomes in Hypertension Drug Labeling

Summary

The Food and Drug Administration (FDA) has made available a guidance for industry that aims to enhance the labeling of antihypertensive drugs to explicitly link lower blood pressure with improved cardiovascular outcomes, a move expected to encourage the appropriate use of these medications in preventing serious cardiovascular events.